Abstract:Background
The infliximab (IFX) is a monoclonal chimeric antibody targeting the Tumor Necrosis Factor alpha (TNFα), indicated in the rheumatoid arthritis (RA) treatment. Only two-third of RA patients respond to anti-TNFα therapy. At this time, predictive factors of response to anti-TNFα are missing. Commercial kit for IFX and antibody toward IFX (ATI) detection in the serum is now available
Objectives
We assessed the development of ATI during one year of IFX treatment in RA patients treated. We also assessed … Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.